NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 to Combat MPox and Measles Outbreaks

Reuters

05-16

<a href="https://laohu8.com/S/NNVC">NanoViricides Inc.</a> Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 to Combat MPox and Measles Outbreaks

NanoViricides Inc. has announced the advancement of its broad-spectrum antiviral drug candidate, NV-387, into Phase II clinical trials. The trials aim to evaluate the drug's effectiveness in treating MPox infections, a pressing medical need given the ongoing pandemic in Africa and spillover cases globally. NV-387 has previously demonstrated promising results in animal models against various viruses, including RSV, Influenza, and Poxviruses. Additionally, the company is preparing for Phase II trials targeting Viral Acute and Severe Acute Respiratory Infections. NanoViricides is also exploring NV-387's potential against Measles and Bird Flu. The company reported financial constraints but plans to secure funding through equity markets and partnerships to continue its development objectives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1028540) on May 16, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2535239833"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535239833\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535239833?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-16 18:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535239833","market":"nz","top_or_hot":-1,"title":"NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 to Combat MPox and Measles Outbreaks","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NNVC\">NanoViricides Inc.</a> Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 to Combat MPox and Measles Outbreaks\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NanoViricides Inc. has announced the advancement of its broad-spectrum antiviral drug candidate, NV-387, into Phase II clinical trials. The trials aim to evaluate the drug's effectiveness in treating MPox infections, a pressing medical need given the ongoing pandemic in Africa and spillover cases globally. NV-387 has previously demonstrated promising results in animal models against various viruses, including RSV, Influenza, and Poxviruses. Additionally, the company is preparing for Phase II trials targeting Viral Acute and Severe Acute Respiratory Infections. NanoViricides is also exploring NV-387's potential against Measles and Bird Flu. The company reported financial constraints but plans to secure funding through equity markets and partnerships to continue its development objectives.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1028540) on May 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 to Combat MPox and Measles Outbreaks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 to Combat MPox and Measles Outbreaks\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-16 18:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NNVC\">NanoViricides Inc.</a> Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 to Combat MPox and Measles Outbreaks\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NanoViricides Inc. has announced the advancement of its broad-spectrum antiviral drug candidate, NV-387, into Phase II clinical trials. The trials aim to evaluate the drug's effectiveness in treating MPox infections, a pressing medical need given the ongoing pandemic in Africa and spillover cases globally. NV-387 has previously demonstrated promising results in animal models against various viruses, including RSV, Influenza, and Poxviruses. Additionally, the company is preparing for Phase II trials targeting Viral Acute and Severe Acute Respiratory Infections. NanoViricides is also exploring NV-387's potential against Measles and Bird Flu. The company reported financial constraints but plans to secure funding through equity markets and partnerships to continue its development objectives.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1028540) on May 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NNVC","symbol_name":"NanoViricides Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nNDL4Rpq2n:1","article_id":"2535239833","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535239833","pubTimestamp":1747391489,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 to Combat MPox and Measles Outbreaks. NanoViricides Inc. has announced the advancement of its broad-spectrum antiviral drug candidate, NV-387, into Phase II clinical trials. The trials aim to evaluate the drug's effectiveness in treating MPox infections, a pressing medical need given the ongoing pandemic in Africa and spillover cases globally. NV-387 has previously demonstrated promising results in animal models against various viruses, including RSV, Influenza, and Poxviruses. Additionally, the company is preparing for Phase II trials targeting Viral Acute and Severe Acute Respiratory Infections. NanoViricides is also exploring NV-387's potential against Measles and Bird Flu. The company reported financial constraints but plans to secure funding through equity markets and partnerships to continue its development objectives.Disclaimer: This news brief was created by Public Technologies  using gener","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NNVC":"NanoViricides Inc.","BK4139":"生物科技","BK4568":"美国抗疫概念"},"translate_title":"NanoViricides Inc.宣布广谱抗病毒药物NV-387的II期临床试验，以对抗MPox和麻疹爆发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NNVC":0.9},"content_text":"NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 to Combat MPox and Measles Outbreaks\n    \n\n        NanoViricides Inc. has announced the advancement of its broad-spectrum antiviral drug candidate, NV-387, into Phase II clinical trials. The trials aim to evaluate the drug's effectiveness in treating MPox infections, a pressing medical need given the ongoing pandemic in Africa and spillover cases globally. NV-387 has previously demonstrated promising results in animal models against various viruses, including RSV, Influenza, and Poxviruses. Additionally, the company is preparing for Phase II trials targeting Viral Acute and Severe Acute Respiratory Infections. NanoViricides is also exploring NV-387's potential against Measles and Bird Flu. The company reported financial constraints but plans to secure funding through equity markets and partnerships to continue its development objectives.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1028540) on May 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}